Drug intelligence / Profile preview

MSM-005

Development stage: Preclinical
Lead developer: MSM Protein Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

MSM-005 is a monoclonal antibody currently in the IND-enabling phase of development for the treatment of undisclosed central nervous system (CNS) indications. Developed by MSM Medical in collaboration with an undisclosed partner, the program targets a membrane protein or a G protein-coupled receptor (GPCR). The specific mechanism of action and biological target remain proprietary, but the asset is part of MSM Medical's pipeline focused on generating antibodies against complex membrane-embedded proteins that are traditionally difficult to target.

Beyond the preview

Go deeper on MSM-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSM-005.

Explore the full profile